JP2013516403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516403A5 JP2013516403A5 JP2012546553A JP2012546553A JP2013516403A5 JP 2013516403 A5 JP2013516403 A5 JP 2013516403A5 JP 2012546553 A JP2012546553 A JP 2012546553A JP 2012546553 A JP2012546553 A JP 2012546553A JP 2013516403 A5 JP2013516403 A5 JP 2013516403A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glatiramer
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 13
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 10
- 229940042385 glatiramer Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 3
- 239000008346 aqueous phase Substances 0.000 claims 3
- 229960003776 glatiramer acetate Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960002989 glutamic acid Drugs 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229920002201 Oxidized cellulose Polymers 0.000 claims 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940107304 oxidized cellulose Drugs 0.000 claims 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29192810P | 2010-01-04 | 2010-01-04 | |
| US61/291,928 | 2010-01-04 | ||
| PCT/IL2010/000679 WO2011080733A1 (en) | 2010-01-04 | 2010-08-19 | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227317A Division JP2016074696A (ja) | 2010-01-04 | 2015-11-20 | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516403A JP2013516403A (ja) | 2013-05-13 |
| JP2013516403A5 true JP2013516403A5 (cg-RX-API-DMAC7.html) | 2013-09-26 |
| JP5916622B2 JP5916622B2 (ja) | 2016-05-11 |
Family
ID=44226217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546553A Active JP5916622B2 (ja) | 2010-01-04 | 2010-08-19 | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
| JP2015227317A Withdrawn JP2016074696A (ja) | 2010-01-04 | 2015-11-20 | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015227317A Withdrawn JP2016074696A (ja) | 2010-01-04 | 2015-11-20 | グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム |
Country Status (21)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| WO2013038399A1 (en) | 2011-09-18 | 2013-03-21 | Bio Plasmar Ltd | Bio-degradable compositions and use thereof |
| WO2014128079A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| MX2016001422A (es) * | 2013-07-29 | 2016-10-05 | Aizant Drug Res Solutions Pvt Ltd | Composicion farmaceutica de fingolimod. |
| WO2015100370A2 (en) * | 2013-12-23 | 2015-07-02 | Kineta One, Llc | Sustained release depot formulations of therapeutic proteins, and uses thereof |
| WO2015140790A1 (en) | 2014-03-17 | 2015-09-24 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| WO2017053346A1 (en) | 2015-09-21 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| US12161688B2 (en) | 2016-06-30 | 2024-12-10 | Mapi Pharma Ltd | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| JP7232752B2 (ja) * | 2016-08-28 | 2023-03-03 | マピ ファーマ リミテッド | 酢酸グラチラマーを含有する微小粒子を調製する方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| JP7193448B2 (ja) * | 2016-08-31 | 2022-12-20 | マピ ファーマ リミテッド | 酢酸グラチラマーを含むデポシステム |
| JP6712003B2 (ja) * | 2016-10-28 | 2020-06-17 | スパインセラＳｐｉｎｅｔｈｅｒａ | 医薬組成物及びその使用 |
| WO2018172850A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| IL316573A (en) * | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| IL269893B2 (en) | 2017-05-15 | 2023-10-01 | Stem Cell Medicine Ltd | Treatment of multiple sclerosis with adipose-derived stem cells |
| CA3062964C (en) * | 2017-05-15 | 2024-11-12 | Mapi Pharma Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| WO2022003662A1 (en) * | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| JP2023550545A (ja) * | 2020-11-02 | 2023-12-01 | シムハ・アイエル－１８・インコーポレイテッド | インターロイキン－１８バリアントおよび使用の方法 |
| WO2022153262A1 (en) | 2021-01-18 | 2022-07-21 | Anton Frenkel | Pharmaceutical dosage form |
| US20220296524A1 (en) * | 2021-01-29 | 2022-09-22 | Tionlab Therapeutics | Initial burst release controlled depot composition and a method thereof |
| US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| CA3227324A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| WO2023170493A1 (en) * | 2022-03-07 | 2023-09-14 | Hadidi Naghmeh | Drug delivery using a parenteral pharmaceutical composition |
| EP4583844A1 (en) * | 2022-09-06 | 2025-07-16 | Regents of the University of Michigan | Biodegradable polymeric particles for delivery of positively charged therapeutic agents |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| DE60112718T2 (de) | 2000-01-20 | 2006-06-29 | Yeda Research And Development Co., Ltd. | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| IL159715A0 (en) * | 2001-07-10 | 2004-06-20 | Teva Pharma | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| DE02800437T1 (de) | 2001-10-03 | 2004-11-11 | The President And Fellows Of Harvard College, Cambridge | Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| CN1398584A (zh) * | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLGA缓释微球及其制备方法和用途 |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| KR101137785B1 (ko) * | 2003-07-18 | 2012-04-25 | 백스터 인터내셔널 인코포레이티드 | 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물 |
| US20060276390A1 (en) * | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| NZ546379A (en) * | 2003-10-31 | 2010-04-30 | Teva Pharma | Nanoparticles for drug delivery |
| KR101242486B1 (ko) | 2004-01-12 | 2013-03-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 장기 전달을 위한 제형 및 그의 이용 방법 |
| NZ549731A (en) | 2004-03-01 | 2009-11-27 | Peptimmune Inc | Methods and compositions for treatment of autoimmune diseases |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| PL2187882T3 (pl) * | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| WO2010011879A2 (en) * | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
-
2010
- 2010-08-19 DK DK18205308.2T patent/DK3536333T3/da active
- 2010-08-19 US US13/258,808 patent/US8796226B2/en active Active
- 2010-08-19 ES ES18205308T patent/ES2928900T3/es active Active
- 2010-08-19 BR BR112012016459A patent/BR112012016459B1/pt active IP Right Grant
- 2010-08-19 MX MX2020003805A patent/MX392126B/es unknown
- 2010-08-19 JP JP2012546553A patent/JP5916622B2/ja active Active
- 2010-08-19 LT LTEP10840699.2T patent/LT2398488T/lt unknown
- 2010-08-19 SI SI201031811T patent/SI2398488T1/sl unknown
- 2010-08-19 PL PL10840699T patent/PL2398488T3/pl unknown
- 2010-08-19 WO PCT/IL2010/000679 patent/WO2011080733A1/en not_active Ceased
- 2010-08-19 HR HRP20221208TT patent/HRP20221208T1/hr unknown
- 2010-08-19 PL PL18205308.2T patent/PL3536333T3/pl unknown
- 2010-08-19 DK DK10840699.2T patent/DK2398488T3/en active
- 2010-08-19 PT PT10840699T patent/PT2398488T/pt unknown
- 2010-08-19 CN CN201710417220.8A patent/CN107184954A/zh active Pending
- 2010-08-19 HR HRP20182076TT patent/HRP20182076T1/hr unknown
- 2010-08-19 PT PT182053082T patent/PT3536333T/pt unknown
- 2010-08-19 SM SM20220422T patent/SMT202200422T1/it unknown
- 2010-08-19 ES ES10840699T patent/ES2699692T3/es active Active
- 2010-08-19 LT LTEP18205308.2T patent/LT3536333T/lt unknown
- 2010-08-19 CN CN2010800606327A patent/CN102686235A/zh active Pending
- 2010-08-19 AU AU2010337822A patent/AU2010337822B2/en active Active
- 2010-08-19 TR TR2018/18858T patent/TR201818858T4/tr unknown
- 2010-08-19 SM SM20190020T patent/SMT201900020T1/it unknown
- 2010-08-19 MX MX2012007760A patent/MX349162B/es active IP Right Grant
- 2010-08-19 CA CA2784394A patent/CA2784394C/en active Active
- 2010-08-19 HU HUE18205308A patent/HUE060304T2/hu unknown
- 2010-08-19 HU HUE10840699A patent/HUE040390T2/hu unknown
- 2010-08-19 MX MX2017009179A patent/MX374215B/es unknown
- 2010-08-19 CN CN201711120362.4A patent/CN107661490B/zh active Active
- 2010-08-19 EP EP10840699.2A patent/EP2398488B1/en active Active
- 2010-08-19 EP EP18205308.2A patent/EP3536333B1/en active Active
-
2015
- 2015-11-20 JP JP2015227317A patent/JP2016074696A/ja not_active Withdrawn
-
2018
- 2018-03-06 HK HK18103162.6A patent/HK1244430A1/zh unknown
- 2018-12-07 CY CY181101307T patent/CY1120975T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516403A5 (cg-RX-API-DMAC7.html) | ||
| TWI242451B (en) | Pharmaceutical dosage forms for controlled release producing at least a timed pulse | |
| Lee et al. | Biodegradable implants for sustained drug release in the eye | |
| CN102548544B (zh) | 同时具有速效特性和长效特性的药物组合物 | |
| HRP20221208T1 (hr) | Depot sustav koji sadrži glatiramer acetat | |
| ES2336913T3 (es) | Comprimido de liberacion modificada de hidrocloruro de bupropion. | |
| KR102356190B1 (ko) | 레보도파 및/또는 레보도파의 에스테르의 점막-점착성, 제어 방출형 제제 그리고 이의 용도 | |
| US8101209B2 (en) | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | |
| Goyal et al. | Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease | |
| US20050037077A1 (en) | Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles | |
| JP6154803B2 (ja) | 膣投与のための迅速溶解性錠剤組成物 | |
| Barua et al. | Drug delivery techniques for buccal route: formulation strategies and recent advances in dosage form design | |
| JP2008520736A5 (cg-RX-API-DMAC7.html) | ||
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| BRPI0518266B1 (pt) | medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular | |
| Venkatraman et al. | An overview of controlled release systems | |
| JP2009512699A5 (cg-RX-API-DMAC7.html) | ||
| Grabovac et al. | Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers | |
| CN113597303B (zh) | 含有阿戈美拉汀的经粘膜治疗系统 | |
| ES2476792T3 (es) | Composición farmacéutica de dosis oral unitaria única que comprende levodopa, carbidopa y entacapona o sales de las mismas | |
| AU2017217464B2 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| WO2018077479A1 (en) | Pharmaceutical compositions comprising a fumaric acid ester and method for the preparation thereof | |
| Sapra et al. | Recent advances in periodontal formulations | |
| EP2994112A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof | |
| Alwossabi et al. | Advancements in Transdermal Drug Delivery Systems: Innovations, Applications, and Future Directions |